This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

John Naitoh, MD; Fred Dorey, PhD; Jean B. deKernion, PhD
UCLA School of Medicine Los Angeles, Calif

JAMA. 1997;278(12):980-981.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Dr Partin and colleagues¹ recently updated their experience using prostate-specific antigen (PSA) level, clinical stage, and tumor grade for predicting the pathological stage of prostate cancer determined at the time of radical prostatectomy.

The authors are to be commended for this herculean effort. However, in examining our own series of radical prostatectomies, our data did not correspond to the outcomes listed in the article. Focusing the analysis of tumors with a Gleason score of 6 or 7, clinical stage of T2b, and PSA levels ranging between 4 and 10 ng/mL, the chance of having organ-confined disease was greater than that reported by Partin et al (70% vs 38% for tumors with Gleason scores of 6 and 50% vs 22% for tumors with Gleason scores of 7). This may be because of the high rate of interobserver variability that exists in clinical staging based on the digital . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?